Skip to main content

Advertisement

SpringerLink
Log in

Clinical efficacy of bortezomib and lenalidomide in blastic plasmacytoid dendritic cell neoplasm

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Bueno C, Almeida J, Lucio P, Marco J, Garcia R, de Pablos JM, Parreira A, Ramos F, Ruiz-Cabello F, Suarez-Vilela D, San Miguel JF, Orfao A (2004) Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica 89:58–69

    CAS  PubMed  Google Scholar 

  2. Martin-Martin L, Lopez A, Vidriales B et al (2015) Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget 6:19204–19216

    Article  PubMed  PubMed Central  Google Scholar 

  3. Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M, Meijer CJLM, Courville P, Joly P, Grange F, de Muret A, Machet L, Dompmartin A, Bosq J, Durlach A, Bernard P, Dalac S, Dechelotte P, D’Incan M, Wechsler J, Teitell MA (2005) Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms). Am J Clin Pathol 123:662–675

    Article  PubMed  Google Scholar 

  4. Sapienza MR, Fuligni F, Agostinelli C et al (2014) Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia 28:1606–1616

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Remco Dijkman RVDK (2007) Gene-expression profiling and array-based CGH classify CD4+CD56+hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood 109:1720–1727

    Article  CAS  PubMed  Google Scholar 

  6. Philippe L, Ceroi A, Bôle-Richard E, Jenvrin A, Biichle S, Perrin S, Limat S, Bonnefoy F, Deconinck E, Saas P, Garnache-Ottou F, Angelot-Delettre F (2017) Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm. Haematologica 102:1861–1868

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, No. 37, Guoxue Xiang, Wuhou District Cancer Center, Chengdu, 610041, China

    Chunli Yang, Chunxi Fu, You Feng, Hongyan Du & Liqun Zou

  2. Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China

    Sha Zhao

  3. Department Medical Oncology, Xiang’an Hospital of Xiamen University, Xiamen, 361000, China

    Huawei Weng

  4. National Cancer Center/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China

    Li Zhang

Authors
  1. Chunli Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chunxi Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. You Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sha Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Huawei Weng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Li Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hongyan Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Liqun Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Each author was involved in the writing of the manuscript. All authors approved the final manuscript.

Corresponding author

Correspondence to Liqun Zou.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Informed consent

Informed consent was obtained from the participating patient of the case description.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, C., Fu, C., Feng, Y. et al. Clinical efficacy of bortezomib and lenalidomide in blastic plasmacytoid dendritic cell neoplasm. Ann Hematol 98, 1525–1527 (2019). https://doi.org/10.1007/s00277-019-03623-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03623-z

Search

Navigation